Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2

Heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma

Tomohiko Asano, Ashwani Khanna, Milagros Lagman, Baogui Li, Manikkam Suthanthiran

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The response rate to IL-2 immunotherapy, currently used in the treatment of metastatic renal cell cancer, is limited. Based on our earlier demonstration that a combined regimen of monoclonal antibodies directed at the T cell surface protein CD3 (anti-CD3 mAbs) and IL-2 is synergistic in constraining tumor progression in a murine fibrosarcoma hepatic metastasis model, we have explored the efficacy of an anti-CD3 mAbs plus IL-2 regimen in a murine renal cell cancer model. Our studies demonstrate that a regimen of anti-CD3 mAbs plus IL-2 is superior to treatment with anti-CD3 mAbs alone or IL-2 alone in reducing the number of pulmonary metastases and in prolonging survival. Moreover, the efficacious regimen is associated with heightened intrapulmonary expression of mRNA encoding cytotoxic attack molecules (perforin, granzyme B) and immunoregulatory cytokines (IL-4, IL-10 and IFN- γ).

Original languageEnglish
Pages (from-to)2396-2401
Number of pages6
JournalJournal of Urology
Volume157
Issue number6
DOIs
Publication statusPublished - 1 Jan 1997
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Monoclonal Antibodies
Cytokines
Messenger RNA
Neoplasm Metastasis
Therapeutics
Fibrosarcoma
Interleukin-4
Interleukin-10
Immunotherapy
Membrane Proteins
T-Lymphocytes
Lung
Liver
Neoplasms

Keywords

  • anti-CD3 mAbs
  • immunotherapy
  • interleukin-2
  • renal cancer

ASJC Scopus subject areas

  • Urology

Cite this

@article{0c8abb34289b43ec83171908a75e327e,
title = "Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: Heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma",
abstract = "The response rate to IL-2 immunotherapy, currently used in the treatment of metastatic renal cell cancer, is limited. Based on our earlier demonstration that a combined regimen of monoclonal antibodies directed at the T cell surface protein CD3 (anti-CD3 mAbs) and IL-2 is synergistic in constraining tumor progression in a murine fibrosarcoma hepatic metastasis model, we have explored the efficacy of an anti-CD3 mAbs plus IL-2 regimen in a murine renal cell cancer model. Our studies demonstrate that a regimen of anti-CD3 mAbs plus IL-2 is superior to treatment with anti-CD3 mAbs alone or IL-2 alone in reducing the number of pulmonary metastases and in prolonging survival. Moreover, the efficacious regimen is associated with heightened intrapulmonary expression of mRNA encoding cytotoxic attack molecules (perforin, granzyme B) and immunoregulatory cytokines (IL-4, IL-10 and IFN- γ).",
keywords = "anti-CD3 mAbs, immunotherapy, interleukin-2, renal cancer",
author = "Tomohiko Asano and Ashwani Khanna and Milagros Lagman and Baogui Li and Manikkam Suthanthiran",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(01)64787-6",
language = "English",
volume = "157",
pages = "2396--2401",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2

T2 - Heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma

AU - Asano, Tomohiko

AU - Khanna, Ashwani

AU - Lagman, Milagros

AU - Li, Baogui

AU - Suthanthiran, Manikkam

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The response rate to IL-2 immunotherapy, currently used in the treatment of metastatic renal cell cancer, is limited. Based on our earlier demonstration that a combined regimen of monoclonal antibodies directed at the T cell surface protein CD3 (anti-CD3 mAbs) and IL-2 is synergistic in constraining tumor progression in a murine fibrosarcoma hepatic metastasis model, we have explored the efficacy of an anti-CD3 mAbs plus IL-2 regimen in a murine renal cell cancer model. Our studies demonstrate that a regimen of anti-CD3 mAbs plus IL-2 is superior to treatment with anti-CD3 mAbs alone or IL-2 alone in reducing the number of pulmonary metastases and in prolonging survival. Moreover, the efficacious regimen is associated with heightened intrapulmonary expression of mRNA encoding cytotoxic attack molecules (perforin, granzyme B) and immunoregulatory cytokines (IL-4, IL-10 and IFN- γ).

AB - The response rate to IL-2 immunotherapy, currently used in the treatment of metastatic renal cell cancer, is limited. Based on our earlier demonstration that a combined regimen of monoclonal antibodies directed at the T cell surface protein CD3 (anti-CD3 mAbs) and IL-2 is synergistic in constraining tumor progression in a murine fibrosarcoma hepatic metastasis model, we have explored the efficacy of an anti-CD3 mAbs plus IL-2 regimen in a murine renal cell cancer model. Our studies demonstrate that a regimen of anti-CD3 mAbs plus IL-2 is superior to treatment with anti-CD3 mAbs alone or IL-2 alone in reducing the number of pulmonary metastases and in prolonging survival. Moreover, the efficacious regimen is associated with heightened intrapulmonary expression of mRNA encoding cytotoxic attack molecules (perforin, granzyme B) and immunoregulatory cytokines (IL-4, IL-10 and IFN- γ).

KW - anti-CD3 mAbs

KW - immunotherapy

KW - interleukin-2

KW - renal cancer

UR - http://www.scopus.com/inward/record.url?scp=0030900415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030900415&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)64787-6

DO - 10.1016/S0022-5347(01)64787-6

M3 - Article

VL - 157

SP - 2396

EP - 2401

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -